Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland
Contributor since / Followers
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) is expanding its manufacturing footprint in Ireland with a $1.8B investment.
The drugmaker will undertake a $1B expansion of its Limerick manufacturing site to boost production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer’s disease.
The latest expansion brings Lilly’s total Limerick investment to $2B, doubling the investment the company announced in March 2023. The company first announced the Limerick site in 2022 and broke ground in March 2023. Production of biologic active ingredients for Lilly medicines is on track to start in 2026.
In addition, the company unveiled its new $800M facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly’s latest diabetes and obesity treatments.
“This additional investment is part of the most ambitious manufacturing expansion agenda in the company’s history. Since 2020, Lilly has committed more than $20 billion to build, expand and acquire manufacturing facilities in the U.S. and Europe,” the company said in a statement.